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Diabetes is widely recognised as one of the leading causes of death and disability worldwide.1 The prevalence of 
diabetes will rise from 6% to over 10% in the next 
decade.2 In 2000, the World Health Organization 
(WHO) recorded a total of 171 million people 
for all age groups worldwide (2.8% of the global 
population) who have diabetes, and the numbers 
are expected to rise to 366 million (4.4% of the 
global population) by 2030.3
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دور اإلجهاد التأكسدي واملواد املضادة لألكسدة يف 
مضاعفات مرض السكري
فاطمة علي، �ستي بلقي�س بودين، زاريانتي عبداحلميد، ن�رص الوهيبي، جمال الدين حممد
امللخ�ص: ُيَعد مر�س ال�سكري اأحد الأمرا�س املزمنة ال�سائعة يف العامل. هناك اهتمام علمي وعام متزايد حول ربط الإجهاد التاأك�سدي مع 
خمتلف احلالت املر�سية مبا فيها مر�س ال�سكري، وكذلك الأمرا�س الأخرى التي ت�سيب الإن�سان. ذكرت الدرا�سات التجريبية وال�رصيرية 
ال�سابقة بـاأن الإجهاد التاأك�سدي يلعب دورا رئي�سيا كُم�سّبب مر�سي ويف تطور م�ساعفات كال النوعني من مر�س ال�سكري. من جهة اأخرى 
اإىل  بحاجة  وتبقى  ناق�سة  ال�سكري  تطور م�ساعفات مر�س  التاأك�سدي يف �رصعة  الإجهاد  بها  ي�ساهم  التي  الدقيقة  الآلية  فاإن معرفة 
تو�سيح اأكرب.من جهة اأخرى، ُيعترب ارتفاع م�ستوى ال�سكر يف الدم اأحد العوامل التي حتث علي اإنتاج اجلذور احلرة، ومن ناحية اأخرى فاإنه 
يوؤدي اإىل �سعف النظام الدفاعي مل�سادات الأك�سدة الداخلي. ت�سمل اآليات دفاع م�سادات الأك�سدة الداخلية كال من امل�سارات الأنزميية 
م�سادات  ت�سمل  لالأك�سجني.  التفاعلية  امل�ستقات  ل�ُسّمية  كم�سادات  دورها  هي  الإن�سان  خاليا  يف  وظائفها  اأهم  ومن  الأنزميية،  وغري 
الأك�سدة الداخلية: الفيتامينات اأ، ج، اإي، جلوتاثيون، والأنزميات، ومنها اأنزمي �سوبراأك�سيد دي�سميوتيز، كاتاليز، جلوتاثيون بريوك�سيديز، 
وجلوتاثيون ريداكتيز. هذه املراجعة ت�سف اأهمية النظام الدفاعي مل�سادات الأك�سدة الداخلية وعالقتها مبختلف  العمليات الف�سيولوجية 
املر�سية واآثارها العالجية املمكنة يف اجل�سم احلي.
والأوعية  القلب  اأمرا�س  احلرة،  اجلذور  ال�سكري،  مر�س  الأك�سدة،  م�سادات  التفاعلية،  الأك�سجني  م�ستقات  تاأك�سدي،  الكلمات:اإجهاد  مفتاح 
الدموية، م�ساعفات مر�س ال�سكري، بريوك�سيد الدهون.
abstract: Diabetes is considered to be one of the most common chronic diseases worldwide. There is a growing 
scientific and public interest in connecting oxidative stress with a variety of pathological conditions including 
diabetes mellitus (DM) as well as other human diseases.  Previous experimental and clinical studies report that 
oxidative stress plays a major role in the pathogenesis and development of complications of both types of DM. 
However, the exact mechanism by which oxidative stress could contribute to and accelerate the development of 
complications in diabetic mellitus is only partly known and remains to be clarified. On the one hand, hyperglycemia 
induces free radicals; on the other hand, it impairs the endogenous antioxidant defense system in patients with 
diabetes. Endogenous antioxidant defense mechanisms include both enzymatic and non-enzymatic pathways. 
Their functions in human cells are to counterbalance toxic reactive oxygen species (ROS). Common antioxidants 
include the vitamins A, C, and E, glutathione (GSH), and the enzymes superoxide dismutase (SOD), catalase 
(CAT), glutathione peroxidase (GPx), and glutathione reductase (GRx). This review describes the importance 
of endogenous antioxidant defense systems, their relationship to several pathophysiological processes and their 
possible therapeutic implications in vivo.
Keywords:  Oxidative stress; Reactive oxygen species; Antioxidants; Diabetic mellitus; Free radicals; Cardiovascular 
diseases; Diabetic complications; Lipid peroxidation.
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Diabetes is a group of metabolic diseases 
characterised by high levels of blood sugar 
(hyperglycemia). It results from defects in insulin 
production and/or insulin action, and impaired 
function in the metabolism of carbohydrates, 
lipids and proteins which leads to long term 
health complications.4,5 In diabetic patients, long-
term damage, dysfunction, and failure of different 
organs, especially the eyes (diabetic retinopathy), 
kidneys (diabetic nephropathy), nerves (diabetic 
neuropathy), heart (myocardial infarction), and 
blood vessels (atherosclerosis) are related to 
uncontrolled hyperglycemia.5–7
However, diabetic patients vary in their 
predisposition to the development of complications.8 
The genetic hypothesis suggests that complications 
from diabetes are genetically predetermined as part 
of the diabetic syndrome, whereas the metabolic 
hypothesis suggests that complications such as 
cellular and vascular damage are the effects of long-
term hyperglycemia.9 The Diabetes Control and 
Complications Trial (DCCT) convincingly showed 
that complications from diabetes can be delayed 
and reduced by maintaining tight glycemic control.9
Role of Oxidative Stress in 
Diabetic Complications
The balance between the rate of free radical 
generation and elimination is important. Excess 
cellular radical generation can be harmful;10 
however, if there is a significant increase in radical 
generation, or a decrease in radical elimination from 
the cell, oxidative cellular stress ensues.11 There is 
convincing experimental and clinical evidence that 
the generation of reactive oxygen species (ROS) 
increases in both types of diabetes and that the 
onset of diabetes is closely associated with oxidative 
stress.2,12
Oxidative stress results from increased ROS 
and/or reactive nitrogen species (RNS).13 Examples 
of ROS include charged species such as superoxide 
and the hydroxyl radical, and uncharged species 
such as hydrogen peroxide and singlet oxygen.2 
The possible sources of oxidative stress in diabetes 
might include auto-oxidation of glucose, shifts in 
redox balances, decreased tissue concentrations of 
low molecular weight antioxidants, such as reduced 
glutathione (GSH) and vitamin E, and impaired 
activities of antioxidant defence enzymes such as 
superoxide dismutase (SOD) and catalase (CAT).14 
ROS generated by high glucose is causally linked to 
elevated glucose and other metabolic abnormalities 
important to the development of diabetic 
complications. However, the exact mechanism 
by which oxidative stress may contribute to 
the development of diabetic complications is 
undetermined.15
In the past few decades, increasing evidence has 
connected oxidative stress to a variety of patholo-
gical conditions, including cancer, cardiovascular 
diseases (CVDs), chronic inflammatory disease, 
post-ischaemic organ injury, diabetes mellitus, 
xenobiotic/drug toxicity, and rheumatoid 
arthritis.16,17 Over time, convincing evidence has 
established the role of free radicals and oxidative 
stress in the pathogenesis and development of 
complications from DM,9,18 including retinopathy, 
nephropathy, neuropathy, and accelerated coronary 
artery disease.19 Several studies have shown 
that elevated extra- and intra-cellular glucose 
concentrations result in oxidative stress20,21 which 
was reported both in experimental diabetes in 
animals and in diabetic patients.21–23 The source of 
oxidative stress is a cascade of ROS leaking from 
the mitochondria. This process has been associated 
with the onset of type 1 diabetes (T1DM) via the 
apoptosis of pancreatic beta-cells, and the onset 
of type 2 diabetes (T2DM) via insulin resistance.21 
The underlying mechanisms in the onset of diabetes 
are complex because hyperglycemia could also be 
due to the cause-effect relationship of increased 
oxidative stress.21 Biomarkers of increased oxidative 
stress, as measured by indices of lipid peroxidation 
and protein oxidation, increase in both T1DM, and 
T2DM.24
The aetiology of oxidative stress in diabetes arises 
from a variety of mechanisms such as excessive 
oxygen radical production from auto-oxidation 
of glucose,25 glycated proteins, and glycation of 
antioxidative enzymes, which limit their capacity 
to detoxify oxygen radicals.20 In addition to these 
mechanisms, two others have been suggested as 
being responsible for the generation of oxygen 
radicals in diabetes. First, Jain demonstrated that 
high glucose levels could stimulate cytochrome 
P450-like activity by excessive nicotinamide 
adenine dinucleotide phosphate-oxidase (NADPH) 
produced by glucose metabolism.26 Second, ketosis, 
a hallmark of T1DM in particular, could increase 
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mRNA expression of transforming growth factor 
beta 1 (TGF-β1) and fibronectin, which are the 
genes implicated in diabetic glomerular injury, 
and 4) inhibition of oxidative stress ameliorates 
all the manifestations associated with diabetic 
nephropathy.36 
Preview studies demonstrated that there is a 
close relationship between endothelial dysfunction 
and the development and progression of renal 
and cardiovascular pathology in patients with 
T1DM.37 The combined development of renal 
and cardiovascular complications is referred 
to as cardiorenal syndrome. The causes of the 
development of cardiorenal syndrome in T1DM 
are poorly understood. Previous studies suggest 
that endothelial dysfunction and the concomitant 
atherosclerotic process may lead to simultaneous 
development and progression of renal and cardiac 
pathology, since endothelial dysfunction is already 
present at the early stages of T1DM.38
Reactive Oxygen Species
Although molecular oxygen is required to sustain 
life, it can be toxic through the formation of 
ROS.39 Indeed, the unusual triplet state of the 
oxygen molecule, due to the presence of two 
unpaired electrons, confers a remarkable chemical 
stability, based on the Pauli Exclusion Principle, 
which forbids reactions between a singlet and a 
triplet molecule. Due to electron spin constraints, 
the oxygen molecule cannot readily react with 
organic substrates.40 Approximately 1–3% of 
oxygen consumed by the body is converted into 
ROS.41 Activation of oxygen can occur through 
two different mechanisms. The first mechanism 
of activation is absorption of sufficient energy to 
reverse the spin on one of the unpaired electrons, 
called a monovalent reduction. The biradical form 
of oxygen is in a triplet ground state because the 
electrons have parallel spins. If triplet oxygen 
absorbs sufficient energy to reverse the spin of one 
of its unpaired electrons, it will become singlet 
oxygen, in which the two electrons have opposite 
spins [Figure 1]. This activation overcomes the spin 
restriction and singlet oxygen can consequently 
participate in reactions involving the simultaneous 
transfer of two electrons (divalent reduction). The 
second mechanism of activation is by the stepwise 
monovalent reduction of oxygen to form superoxide 
oxygen radical production in diabetic patients.27
Nowadays, diabetic micro- and macroangiopathy 
are considered to be poly aetiological multifactorial 
diseases. A number of studies have evaluated the role 
of oxidative stress in the aetiology of microvascular 
and macrovascular complications of diabetes in 
the fasting state.28 Furthermore, there is growing 
evidence suggesting the role of hyperglycemia, 
hyperinsulinemia and dyslipidaemia in diabetic 
patients, all of which have been implicated in 
the development of macroangiopathies, which 
possibly act upon their ability to induce oxidative 
stress, leading to endothelial dysfunction and 
atherosclerosis.20 Many studies have suggested that 
oxidative stress is a common pathogenic factor for 
the dysfunction of beta and endothelial cells.29,30 
Beta cell dysfunction results from prolonged 
exposure to high glucose, elevated free fatty acid 
(FFA) levels, or a combination of both.30 Beta cells 
are particularly sensitive to ROS because they 
are low in free-radical quenching (antioxidant) 
enzymes such as catalase (CAT), glutathione 
peroxidase (GPx) and superoxide dismutase 
(SOD).31 Therefore, the ability of oxidative stress to 
damage mitochondria and markedly blunt insulin 
secretion is not surprising.32,33 For example, it has 
been demonstrated that oxidative stress generated 
by short exposure of beta cell preparations to 
hydrogen peroxide (H2O2) increases the production 
of protein cyclin-dependent kinase inhibitor 1 (p21) 
and decreases insulin messenger ribonucleic acid 
(mRNA), cytosolic adenosine triphosphate (ATP), 
and calcium flux in cytosol and mitochondria.34 In 
other studies, much experimental evidence has been 
accumulated to show that various types of vascular 
cells are able to produce ROS under hyperglycemic 
conditions.20 
The pathogenesis of diabetic nephropathy 
remains far from clear. An important role of 
oxidative stress for the development of nephropathy 
and neurological complications is suggested by 
experimental and clinical studies.35 These studies 
establish a causal relationship between oxidative 
stress and diabetic nephropathy by observations that 
1) lipid peroxides and 8-hydroxydeoxyguanosine, 
indices of oxidative tissue injury, increase in the 
kidneys of diabetic rats with albuminuria; 2) 
high glucose directly increases oxidative stress 
in glomerular mesangial cells and target cells of 
diabetic nephropathy; 3) oxidative stress induces 
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(O2), H2O2, hydroxyl radical (OH) and finally water 
according to the scheme shown in Figure 2. The first 
step in the reduction of oxygen forming superoxide 
is endothermic, but subsequent reductions are 
exothermic.42
Humans are exposed to many carcinogens, 
but the most significant may be the reactive 
species derived from the metabolism of oxygen 
and nitrogen known as ROS and RNS. On the one 
hand, the formation of ROS and RNS in the human 
body can cause oxidative damage to biological 
macromolecules, especially the plasma membrane,43 
which may contribute to the development of cancer, 
CVD, diabetes and other oxidative stress-mediated 
dysfunctions.44 On the other hand, ROS are known 
mediators of intracellular signalling cascades.45 
Even though ROS are generated under 
physiological conditions and are involved to 
some extent as signalling molecules and defence 
mechanisms as seen in phagocytosis, neutrophil 
function, macrophages and other cells of immune 
system,46 ROS are a heterogeneous group of 
molecules that are generated by mature myeloid 
cells during innate immune responses, and are 
also implicated in normal intracellular signalling. 
When phagocytes are activated, they produce ROS 
in amounts high enough to kill intruding bacteria.47 
Also, shear-stress induced vasorelaxation and 
excess production of ROS may, on the other hand, 
lead to oxidative stress, loss of cell function, and 
ultimately to apoptosis or necrosis.46 ROS are 
produced by oxidative phosphorylation, NADPH, 
xanthine oxidase, the uncoupling of lipoxygenases, 
cytochrome P450 monooxygenases, and glucose 
autoxidation.18 Once formed, ROS deplete 
antioxidant defenses, rendering the affected cells 
and tissues more susceptible to oxidative damage 
by reacting with lipids in cellular membranes, 
nucleotides in DNA,48 sulphydryl groups in 
proteins, and cross linking fragmentation of 
ribonucleoproteins,49 leading to changes in cellular 
structure and function.19
 Levels of ROS are under tight control by the 
protective actions of antioxidant enzymes and non-
enzymatic antioxidants in normal and healthy cells. 
However, in diabetes, excessive cellular levels of 
ROS are induced by hyperglycemia causing a major 
complication of DM.50 Furthermore, in the case of 
diabetes or insulin resistance, a higher oxidative 
glucose metabolism itself increases mitochondrial 
production of O2 ●  which will then be converted to 
OH● and H2O2.
51 Beyond glucose, ROS formation is 
also increased by FFAs, through its direct effect on 
mitochondria.52 It has been proposed that over-
expression and activity of mitochondrial inner 
membrane uncoupling proteins (UCPs) contribute 
to an increase in superoxide formation under 
diabetic conditions.53
The ROS52,54 listed in Table 1 include free radicals 
such as superoxide (O2 ●) hydroxyl (OH●), and 
RNS52,54 include free radicals like nitric oxide (NO●). 
Of these reactive molecules, O2 ●, NO●and 
ONOO  are the most widely studied species and 
play important roles in diabetic cardiovascular 
complications.12
In diabetes, NADPH oxidase is a major source of 
the generation of ROS. NADPH oxidase is located 
in the plasma membrane of various renal cell 
types, including mesangial and proximal tubular 
cells, vascular smooth muscle cells, endothelial 
cells, and fibroblasts. NADPH oxidase-dependent 
Figure 1: Nomenclature of the various forms of 
oxygen.42
Figure 2: The activation states of oxygen.42
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structures alter the relative susceptibility of certain 
amino acids.42 Experimental studies show that the 
decrease in the total protein concentration in the 
serum of diabetes-induced rats may be ascribed 
to: 1) decreased amino acids uptake;55 2) a greatly 
decreased concentration of a variety of essential 
amino acids;56 3) an increased conversion rate of 
glycogenic amino acids to CO2 and H2O, and 4) 
a reduction in protein synthesis secondary to a 
decreased amount and availability of mRNA.57
In vitro studies show that myeloperoxidase, 
a heme protein secreted by neutrophils and 
monocytes, catalyses a very specific reaction, leading 
to the conversion of L-tyrosine to 3-3-dityrosine.58 
In addition, the oxidative formation of dityrosine in 
proteins may serve as a crosslink between adjacent 
polypeptide chains of the same or different proteins. 
Dityrosine is a very unusual molecule linked not 
by a peptide, but by a covalent bond resistant to 
protolytic degradation and acid hydrolysis.59 This 
property of dityrosine makes it a convenient marker 
for protein oxidation. Oxidatively induced cross-
linking of proteins with this modified amino acid 
was suggested to be a signal for rapid and selective 
in vivo degradation by intracellular protease.60 
However, accumulation of oxidatively modified 
proteins with age was thought to be a result of their 
increased resistance to degradation.61 
b. lipids
In recent years, much attention has been focused 
on the role of oxidation stress, and it has been 
reported that the imbalance between oxidative 
stress measures and antioxidant levels in diabetes 
is present because of the generation of ROS during 
glycation, and glucose and lipid oxidation.62,25 Lipid 
hydroperoxides (LHP), produced from a variety of 
long-chain polyunsaturated fatty acid precursors 
via intermediate radical reactions, involve oxygen 
and metal cations (iron and copper). The net result 
of these combined reactions is the generation 
of highly reactive and cytotoxic lipid radicals, 
which generate new LHP because of their close 
proximity in biomembranes to other lipids.63 In 
addition, diabetes produces disturbances of lipid 
profiles, especially an increased susceptibility to 
lipid peroxidation,64 which is responsible for an 
increased incidence of atherosclerosis,65 a major 
complication of DM.66 Lipid peroxidation is a 
critical biomarker of free radical-mediated oxidative 
overproduction of ROS plays a key role in 
promoting hyperglycemia-induced oxidative stress. 
The NADPH oxidase increase oxidative stress and 
finally this increases results in the development of 
diabetic nephropathy in rats.47 
Oxidative Stress-Induced 
Cellular Damage
The targets of ROS damage include all major groups 
of biomolecules and can be described as follows:
a. proteins 
Since ROS can target almost all cellular 
compounds, several studies report that ROS can 
react with several amino acid residues in vitro, 
generating anything from modified and less active 
enzymes to denatured, non-functioning proteins.55 
Fragmentation of the peptide chain and aggregation 
of cross-linked reaction products result in an altered 
electrical charge and increased susceptibility to 
proteolysis.42 The amino acids in a peptide differ 
in their susceptibility to attack, and the various 
forms of activated oxygen differ in their potential 
reactivity. Primary, secondary, and tertiary protein 
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stress, and it is probably the most explored area 
of research when it comes to ROS.67 It is also an 
important pathological indicator in many diseases.56 
Consequently, mechanisms in the formation of lipid 
hydroperoxides and biologically active metabolites, 
together with their effect on cellular structure and 
function, are of increasing importance to the study 
of diabetogenesis.68
There is much evidence from experimental 
studies that polyunsaturated fatty acids (PUFA) in 
the plasma membrane, because of their multiple 
double bonds, are extremely susceptible to attack 
by free radicals.69 Hydroxyl radicals initiate a free 
radical chain reaction and remove a hydrogen 
atom from one of the carbon atoms in the PUFA 
and lipoproteins, causing lipid peroxidation 
characterised by membrane protein damage 
through subsequent free radical attacks.70 One 
major hypothesis as to why this occurs is that 
oxidised lipoprotein (oxLDL) contributes to the 
cardiovascular complications of diabetes. Low-
density lipoprotein (LDL) is the major cholesterol 
carrier in plasma, and elevated levels of circulating 
LDL are associated with increased risk for 
atherosclerosis; notably, increased levels of oxLDL 
have been associated with hypertension in men.71 
Several studies have demonstrated increased 
LDL oxidation in diabetic patients when compared 
to their corresponding controls.72 Oxidised lipids 
can affect cell function by accumulating in the cell 
membrane causing leakage of the plasma lemma 
and interfering with the function of membrane-
bound receptors.73 In addition, the by-products of 
lipid peroxidation, such as unsaturated aldehydes 
and other metabolites, have cytotoxic and mutagenic 
properties, and oxLDL itself has a specific role in 
the pathogenesis of atherosclerosis.74 The effects 
of oxLDL on the vessel walls themselves include 
stimulation of cytokine and growth factor production 
and generation of endothelial dysfunction, including 
inhibition of endothelial cell vasodilator function, 
all of which contribute to atherosclerosis.41 Lipid 
peroxidation-mediated membrane defects have also 
been implicated in the decreased reactivity of thiol 
group membrane proteins.75 As a consequence, 
enriching the membranes with PUFA could restore 
oxidative membrane damage and subsequently 
normalise decreased membrane fluidity and 
function. Antioxidants (i.e., dietary supplements) 
compensating for loss of PUFA may enhance the 
activity of transmembrane enzymes, membrane-
embedded receptors and membrane transport 
systems.52
Role of Antioxidant 
Defense System and 
Protection Mechanism
In the late 19th and early 20th centuries, chemists 
studied antioxidants, a loosely defined group of 
compounds characterised by their ability to be 
oxidised in place of other compounds present. At 
first, their uses ranged from food storage to the 
vulcanisation of rubber, but it was only later that 
biologists realised the importance of antioxidants in 
health with the 1960s publications of vitamins and 
flavanoids.39 In the 1970s, Cameron and Pauling, 
followed by later research, found that ascorbic acid 
(vitamin C) is a potential human cancer protective 
agent.76 With many well-known scientists actively 
researching antioxidants as protecting agents,77 
explanations for the effects of antioxidants on 
cancer susceptibility and overall health expanded 
rapidly in subsequent decades with research into 
mechanisms, molecular targets, and molecular 
interactions.78 In recent years, many conferences 
and reviews testify to the increasing interest in the 
roles of the body's antioxidants system working 
together in human cells against toxic reactive 
oxygen species, their relationship with several 
pathophysiologic processes and their possible 
therapeutic implications.79
Antioxidant defense mechanisms involve both 
enzymatic and nonenzymatic strategies. Common 
non-enzymatic antioxidants include the vitamins 
A, C, and E, glutathione, α-lipoic acid, mixed 
carotenoids, coenzyme Q10 (CoQ10), several 
bioflavonoids, antioxidant minerals (copper, zinc, 
manganese and selenium), and cofactors like 
folic acid, uric acid, albumin, and vitamins B1, 
B2, B6, and B12. Enzymatic antioxidants include 
superoxide dismutase, catalase, glutathione 
peroxidase, and glutathione reductase.80 Through 
normal physiological processes, antioxidants affect 
signal transduction and regulation of proliferation 
and the immune response. While ROS have been 
linked to cancer, diabetic complications and CVD, 
antioxidants have shown promise as a possible 
therapy for the prevention and treatment of these 
diseases, especially given the tantalising links 
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a significantly improved lipid composition, and 
maintenance of membrane fluidity in the brains of 
the rats.84  Coleman suggested that triple antioxidant 
therapy (vitamin E, lipoic acid [LA] and vitamin C) 
in diabetic volunteers attenuates the experimental 
oxidative stress of methemoglobin formation in 
vitro and reduces haemoglobin glycation in vivo.85 
Panjwani suggested that vitamin C administered 
alone or in combination with vitamin E reduced the 
fall in ulnar nerve conduction velocity.86
Sivan and Reece investigated whether dietary 
supplementation with vitamin E would reduce the 
incidence of diabetic embryopathy in an in vivo 
rat model.87 Fifty pregnant rats were designated as 
the control group and received a normal diet while 
the diabetic group received vitamin E supplements 
(400 mg/day). This experimental study found 
that supplementation with vitamin E reduces the 
incidence of neural tube defects by more than 75%.87 
These findings suggest that vitamin E reduces this 
oxidative load, confers a protective effect against 
diabetic embryopathy, and thus may potentially 
serve as a dietary prophylaxis in the future. 
These results are in line with the reports from 
Chang and others which showed that diabetic 
embryopathy of rat or mouse embryos is prevented 
by vitamin C, vitamin E, SOD, N-acetyl-cysteine, 
or glutathione ethyl ester.88 Another study by Otero 
et al. showed the effects of supplementation with 
vitamin E to diabetic mice. The beneficial effect 
of vitamin E observed in this model was shown to 
retard coronary atherosclerosis accelerated by DM, 
and was demonstrated to be due to a reduction in 
oxidative stress, and not secondary to a decrease in 
plasma glucose or cholesterol since their respective 
plasma concentrations remained unchanged in the 
diabetic mice supplemented with vitamin E.89 
Furthermore, it has been recently reported that 
macrophages from diabetic mice are under excess 
oxidative stress, and that the antioxidant vitamin E 
can attenuate macrophage oxidative stress which 
exists in DM and leads to accelerated atherosclerosis 
development.90 In addition, there have been other 
experimental studies assessing the prophylactic 
effects of vitamin E against heart failure in type 1 
diabetic cardiomyopathy. These studies have found 
that supplementation of streptozotocin-induced 
(STZ)-diabetic rats with 2000 IU of vitamin E/
kg of feed beginning immediately after induction 
of DM and continuing for 8 weeks provided a 
observed between diets high in fruits and vegetables 
(and presumably antioxidants) and decreased 
risks of cancer.41 Evidence from experimental, 
epidemiological and clinical studies have proven 
the utility of antioxidants which might therefore be 
helpful for treating diabetes and its complication.
Evidence from 
Experimental Studies
Worldwide, several animal studies on antioxidants 
as protective agents have been conducted. The 
most important studies have been performed 
utilising antioxidants in experimental diabetic 
models. The effects of antioxidants on oxidative 
stress are measured through certain observable 
biomarkers. These markers include the enzymatic 
activities of CAT, SOD, GSH-Px, and glutathione 
reductase (GSH-Rx), as well as thiobarbituric acid 
reacting substances (TBARS) levels, an indirect 
measurement of free radical production that has 
been shown to be consistently elevated in diabetes.12 
Kunisaki investigated the effects of treatments 
with classical antioxidants such as vitamin E, 
vitamin C and lipoic acid. Specifically, vitamin E 
normalises retinal blood flow and protein kinase 
C (PKC) activity in the vascular tissue of diabetic 
rats.81 One short-term experimental study showed 
that high doses of vitamin C can improve some 
aspects of endothelial dysfunction in diabetes.82 
Another experimental study has demonstrated 
that intraperitoneal administration of α-lipoic 
acid to streptozotocin (STZ) diabetic Wistar rats 
normalises TBARS levels in plasma, and the retina, 
liver, and pancreas.83 Furthermore, it has been 
reported that α-lipoic acid leads to a decrease in the 
severity of diabetic neuropathy by maintaining GSH 
levels and/or by its direct antioxidant properties.83 
However, lipoic acid administration improved 
endothelial function in subjects with metabolic 
syndrome. 
In another study to determine the effects of 
vitamin E on oxidative stress and cell membrane 
fluidity in the brains of diabetes-induced 
experimental rats, Hong et al. reported that vitamin 
E was found to be effective for strengthening the 
antioxidant defense system. They noted a reduction 
of the accumulation of ROS such as superoxide 
radicals, a decrease in the generation of oxidative 
damaging substances such as the carbonyl value, 
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significant protection against cardiac dysfunction 
induced by T1DM. This cardioprotective effect 
was simultaneously associated with the ability of 
vitamin E to blunt diabetes-induced amplification 
of myocardial infarction.91 These findings suggest 
the usefulness of vitamin E supplementation during 
the early phases of T1DM for the prophylaxis of 
cardiomyopathy and subsequent heart failure.
Ozkan et al. examined the protective effects 
of a triple antioxidant combination (vitamins 
E and C plus α-lipoic acid) on the total lipid and 
cholesterol levels and the fatty acid composition 
of brain tissues in experimental diabetic and non-
diabetic rats. Vitamin E and α-lipoic acid were 
injected intraperitoneally (50 mg/kg) four times per 
week and vitamin C was provided as a supplement 
dissolved in the rats’ drinking water (50 mg/kg). The 
result of this study confirms that treatment with a 
triple combination of antioxidants protects the 
arachidonic acid level in the brains of diabetic and 
non-diabetic rats. In addition, both antioxidants 
and insulin treatment have beneficial effects on the 
D-6 desaturase system and unsaturated fatty acid 
levels. Antioxidants may also have protective effects 
on unsaturated fatty acids, and reduce oxidative 
stress, thus impairing the progression to LDL 
oxidation, cell membrane lipid peroxidation and 
decreased endoneurial blood flow, thereby reducing 
peripheral nerve and vascular dysfunction.92
Evidence from Clinical 
Studies
Early interest in the use of vitamin E supplementation 
in patients with CHD came from the enthusiastic 
reports of a Canadian physician, Evan Shute, who 
recommended vitamin E for all his patients with 
coronary heart disease (CHD) and presented a case 
series showing its significant benefit in reducing 
symptoms of angina pectoris.93 In a clinical trial 
study conducted by Bursell, et al., they evaluated 
36 patients with T1DM. In their crossover trial, 
individuals were divided into two groups; one group 
received a placebo while the other group received 
high dose vitamin E supplementation (1,800 IU/
day). The major aim of this study was to determine 
the effectiveness of vitamin E in normalising retinal 
blood flow and renal function in patients with 
T1DM. They found that oral vitamin E treatment 
appears to be effective in normalising retinal 
haemodynamic abnormalities and improving renal 
function in patients with T1DM, especially those 
with short disease duration, without inducing a 
significant change in glycemic control. This suggests 
that vitamin E supplementation may provide 
an additional benefit in reducing the risks for 
developing diabetic retinopathy or nephropathy.94
In terms of vitamin E supplementation in 
diabetes, Ross and others have demonstrated 
beneficial effects on cataract genesis in diabetic 
rats.95 Furthermore, in a study done over a four 
month period, Paolisso, et al. evaluated the efficacy 
of oral supplementation of vitamin E (900 mg\day) 
in T2DM patients. They found that supplementation 
of vitamin E decreased lowered insulin resistance 
and improved glucose uptake as shown by 
euglycemic glucose clamp assays performed both 
before and after the supplementation period.96 In 
addition, they also concluded that vitamin E may 
be a useful adjunct in reducing oxidative stress in 
T2DM. These findings confirmed an earlier study 
by Ceriello et al. in which glycosylated haemoglobin 
and other proteins were significantly decreased 
after two months’ treatment with either 600 or 1200 
mg/day of vitamin E.97 The potential for vitamin E 
in pharmacological doses to be used as a means 
to delay or prevent secondary complications of 
diabetes seems well established. 
Vitamin C supplementation is effective in 
reducing sorbitol accumulation in the red blood cells 
of diabetics. These findings have been confirmed by 
a clinical study carried out by Cunningham, et al., 
who investigated the effect of two different doses of 
vitamin C supplements (100 and 600 mg) during a 
58 day trial on young adults with T1DM. The results 
of this study showed that within 30 days, vitamin C 
supplementation at either dose normalised sorbitol 
levels in those with diabetes. Furthermore, vitamin 
C also helps to reduce capillary fragility which also 
contributes to complications from DM. Moreover, 
several studies suggest that chronic vitamin C 
administration has beneficial effects on glucose and 
lipid metabolism in T2DM patients.98 In addition, 
vitamin C supplementation improved glycemic 
control, fasting blood glucose levels, cholesterol and 
triglycerides.99
In a placebo-controlled, randomised trial of 
diabetic patients, Reaven investigated the effect 
of 1600 IU of RRR-α-tocopherol supplementation 
daily for 10 weeks on hyperglycemia-induced LDL 
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effect of RRR-α-tocopherol supplementation on 
the hyperglycemia-induced LDL modifications in 
T1DM and T2DM diabetic patients.100
Based on nutrition recommendations and 
interventions for diabetes, there is no clear evidence 
of benefits that can be derived from vitamin or 
mineral supplementation in people with diabetes. 
Routine supplementation with antioxidants, such 
as vitamins E and C and carotene, is not advised 
because of lack of evidence of efficacy, and concern 
related to long term safety, and therefore cannot be 
recommended.102 The majority of studies included 
in this review support a possible role of antioxidant 
supplementation in reducing the risk of CVD and 
diabetic complications. However, the results of the 
majority of the prospective randomised controlled 
modifications. The result of the study pointed to 
a reduction of approximately 60% of plasma LDL 
oxidation in diabetic patients, which was statistically 
significant when compared to healthy controls.100 
These results are supported and confirmed by 
other similar clinical data. Salonen, et al. found that 
doses equal to or higher than 450 IU are sufficient 
to significantly ameliorate the susceptibility of 
LDL to oxidation, indicating that relatively high 
doses of RRR-α-tocopherol for supplementation 
are needed.101 Furthermore, Bellomo and others 
have shown that the effects of RRR-α-tocopherol 
supplementation on LDL oxidation are accompanied 
by a concomitant reduction in autoantibody levels 
against hyperglycemia-induced LDL modifications. 
Moreover, clinical studies have shown an inhibitory 
Table 2: Selected controlled clinical trials of antioxidant supplements’ effect on preventing diabetic complications
Study name with type of 
supplementation
Number Sex Age Dose Duration in years 





11,324 M, F No age limits 300 mg 3.5 Y No effect on MI + 
CVD death + stroke
Yusuf, et al. 2000107 
Vitamin E
9541 M, F ≥55 400 IU 4.5 Y No effect on MI, CVD 
death, or  stroke
Pruthi, et al. 2001108 
Vitamin E
39,910 M No age limits 100 IU/day 2 Y 37% lower risk of 
CHD
Kritharides, et al. 2002109 
Vitamins A and C, folic 
acid, niacin,β-carotene, 
selenium, zinc 
87,000 M, F No age limits Not 
available
10 Y Significantly lower risk 
of CVD, mortality
Deepak, et al. 2003105 
Vitamins E and C, and 
β-carotene









incidence of vascular 
events between 
vitamin and placebo 
groups
Lee, et al. 2005110 
Vitamin E
40000 F ≥45 600 IU 10 Y No effect on  
cardiovascular events
Costacou, et al. 2006111 
Vitamin supplementation 
with multivitamin pills 
M, F <17 Multivit-
amin pills 
10 Y Significant decreased 
risk of CAD incidence 
in  T1DM
Milman, et al. 2008112 
Vitamin E
1434 M, F ≥55 400 U/day 18 M Reduced 
cardiovascular events 
in individuals with 
DM
Hodis, et al. 2009113  
Folic acid, Vitamin B12, 
and B6








low risk for CVD
Shargorodsky, et al. 
2010114 
Combined antioxidant 
(Vitamins E and C, 
coenzyme Q10)






6 M Positive effects on 
cardiovascular risk 
factors
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antioxidant clinical trials have failed to demonstrate 
a significant benefit in antioxidant supplementation 
in the prevention of atherosclerotic events, as shown 
in Table 2. As also supported by more recent meta-
analysis studies of antioxidant-intervention trials in 
humans, doses of vitamin E supplements (400 or 
800 IU) given in many clinical trials are associated 
with adverse effects,103 or are associated with an 
increased risk of death.104 Furthermore, the results 
of the majority of the prospective randomised 
controlled antioxidant clinical trials have failed to 
demonstrate a significant benefit of antioxidant 
supplementation (vitamins C, E and β-carotene) 
in primary patients (i.e. those without clinical 
evidence of CVD) or secondary patients (i.e. those 
with clinical evidence of CVD) in the prevention of 
cardiovascular events.105 Moreover, in clinical trials 
the supplementation of vitamins C and E, and/or 
β-carotene was associated with an increased risk 
for all-cause mortality, a finding also supported by a 
recent meta-analysis.104 
Conclusion
In conclusion, there is considerable evidence that 
induction of oxidative stress is a key process in 
the onset of diabetic complications. The precise 
mechanisms by which oxidative stress may accelerate 
the development of complications in diabetes are 
only partly known. Evidence for the protective 
effect of antioxidants has been presented in 
experimental, clinical, and epidemiological studies, 
which have demonstrated that antioxidants might 
be helpful in treating diabetes and its complications. 
In contrast, the results of the majority of the 
prospective randomised controlled antioxidant 
clinical trials have failed to demonstrate a significant 
benefit, in the prevention of cardiovascular events, 
of antioxidant supplementation (vitamins C, E and 
β-carotene) in primary patients without clinical 
evidence of CVD, or in secondary patients with 
clinical evidence of CVD. 
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